Categories Earnings, Health Care
Regeneron Pharmaceuticals (NASDAQ: REGN): Q3 2019 Earnings Snapshot
— Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter 2019 adjusted earnings of $6.67 per share versus $6.36 per share expected.
— Total revenues grew by 23% to $2.05 billion versus $1.99 billion expected. Eylea sales increased by 16% to $1.19 billion.
— Dupixent sales, which soared by 141% to $633 million, drove higher profitability from antibody collaboration with Sanofi.
— Looking ahead into the full year 2019, the company lowered the Sanofi collaboration revenue outlook to the range of $490 million to $510 million from the prior range of $500 million to $530 million.
— Unreimbursed R&D expense, on a reported basis, is now expected to be $2.36 billion to $2.41 billion, and SG&A expense is now predicted to be between $1.73 billion and $1.78 billion for 2019.
— The forecast for capital expenditure is tightened to the range of $390 million to $420 million from the previous range of $380 million to $420 million for the full year.
Most Popular
Major earnings conferences to watch this week
After registering a slow recovery in the first half of the week, the markets pared these gains on Thursday and Friday. The weakness witnessed in the latter half of the
Illumina (ILMN) is uniquely placed to offer long-term returns. Here’s why
Illumina, Inc. (NASDAQ: ILMN), a pioneer in genome sequencing technology, has strived to strengthen its unique position in the healthcare sector through strategic partnerships and technological innovation. Its performance so
The COVID-19 pandemic gave these companies an unexpected opportunity
The COVID-19 pandemic raged through the first half of this year and continues to impact the world without signs of abating. Amid this health crisis, several companies reported strong results
One thought on “Regeneron Pharmaceuticals (NASDAQ: REGN): Q3 2019 Earnings Snapshot”
Comments are closed.